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Abstract
Background: Symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema in children cluster 
at both the individual and population levels. 
Objectives: To assess individual-level and school-level risk factors for symptoms of rhinoconjunctivitis 
and compare them to corresponding associations with symptoms of asthma and eczema in Phase 
Three of the International Study of Asthma and Allergies in Childhood. 
Methods: We studied 116,863 children aged 6-7 years from 2,163 schools in 59 centres and 22 
countries and 224,436 adolescents aged 13-14 years from 2,037 schools in 97 centres in 41 countries. 
Multilevel logistic regression models were fitted with random intercepts for school, centre and 
country, adjusting for sex and maternal education at the child level. Associations between symptoms 
and a range of lifestyle and environmental risk factors were assessed for both the child’s exposure and 
mean exposure at the school. Models were fitted for rhinoconjunctivitis, asthma and eczema singly 
(unimorbidity) and for combinations of these conditions (multimorbidity). 
Results: Generally, associations between symptoms and exposures at the school level were similar in 
direction and magnitude to those at the child level. Associations with multimorbidity were stronger 
than for unimorbidity, particularly in individuals with symptoms of all three diseases, but risk factor 
associations found in conventional single disease analyses persisted among children with only one 
condition, after excluding multimorbid groups. 
Comparisons of individuals with only one disease showed that many risk factor associations were 
consistent across the three conditions. More strongly associated with asthma were low birthweight, 
cat exposure in infancy and current maternal smoking. Current paracetamol use was more strongly 
associated with asthma and rhinoconjunctivitis than eczema. Breastfeeding was more strongly 
associated with eczema than asthma or rhinoconjunctivitis. 
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The direction and magnitude of most risk factor associations were similar in affluent and non-affluent 
countries, although notable exceptions include farm animal contact in infancy and larger sibships, 
which were associated with increased risk of rhinoconjunctivitis in non-affluent countries but reduced 
risk in affluent countries. In both age groups, current paracetamol use increased risk of each disease 
to a greater extent in affluent countries than in non-affluent countries. Effects of paracetamol and 
antibiotics in infancy were more consistent between richer and poorer settings. 
Conclusions: Most of the environmental and lifestyle correlates of rhinoconjunctivitis, asthma and 
eczema in childhood display similarity across the three conditions, even in less affluent settings where 
allergic sensitisation is less likely to explain the concordant epidemiological patterns.  
Trial registration: Not applicable. 
Keywords
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Multimorbidity 
Global
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Introduction
The International Study of Asthma and Allergies in Childhood (ISAAC) has used standardised 
questionnaires to assess prevalence, time trends and epidemiological associations for symptoms of 
non-infective rhinoconjunctivitis, asthma and eczema among children from over 300 centres in more 
than 100 countries worldwide [1,2]. More detailed biomedical assessment in 30 diverse centres in 
ISAAC Phase Two [3-5] has demonstrated that allergic sensitisation accounts for a much lower 
proportion of rhinoconjunctivitis, asthma and eczema symptoms in centres from low- and middle-
income countries than it does in more affluent settings which feature more prominently in the 
epidemiological literature. 
Previous publications from ISAAC Phase Three have presented the associations of each of the three 
diseases with single environmental or lifestyle factors [6-19]. More recently, these have been 
summarised across multiple risk factors for symptoms of asthma [20] and eczema [21], and 
comparisons made between the relationship of each of these diseases to exposures measured at the 
level of individuals and exposures averaged at the area level (schools). 
In this paper, we apply the multi-level analytical approach to symptoms of rhinoconjunctivitis and 
extend our overview to assess similarities and differences in the epidemiological patterns of the three 
diseases, singly and in combination. We also compare these patterns between centres from higher-
income and lower-income countries. 
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Methods 
Study design 
A brief summary of the ISAAC Phase Three methods are presented in this paper and more details are 
available elsewhere [1]. ISAAC Phase Three was a multi-centre, multi-country, cross-sectional study of 
children (age 6-7 years) and adolescents (age 13-14 years). Within a defined geographical area 
(centre), a sample of schools were chosen at random. All children within the age groups in those 
schools were asked to participate [1].  The Phase Three survey took place in 2000-2003 and included 
two standardised questionnaires (http://isaac.auckland.ac.nz); the original symptom questionnaire 
from ISAAC Phase One [1-2] with information on symptoms of asthma, eczema and 
rhinoconjunctivitis, and an environmental questionnaire which collected data on a range of possible 
risk factors for the development of these disorders [1].  
Variable definitions 
The three main outcomes of interest, asthma, eczema and rhinoconjunctivitis, are defined using 
previous ISAAC conventions [1-3]. These three diseases are likely to be undiagnosed in many cases as 
people seek to self-treat (particularly rhinoconjunctivitis), and the rate of doctor diagnoses is likely to 
vary widely from country to country. Thus, outcomes assessed in the ISAAC questionnaire are based 
on a description of symptoms rather than a diagnosis of disease.  
Rhinoconjunctivitis is defined by positive responses to all of the following three questions: 
Have you [has your child] ever had a problem with sneezing, or a runny, or blocked nose when 
you did not have a cold or the flu? 
In the past 12 months, have you [has your child] had a problem with sneezing, or a runny, or 
blocked nose when you [he/she] did not have a cold or the flu? 
In the past 12 months, has this nose problem been accompanied by itchy-watery eyes?
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Eczema is defined by positive responses to all of the following three questions: 
Have you [has your child] ever had an itchy rash which was coming and going for at least six 
months? 
Have you [has your child] had this itchy rash at any time in the past 12 months? 
Has this itchy rash at any time affected any of the following places: the folds of the elbows, 
behind the knees, in front of the ankles, under the buttocks, or around the neck, ears or eyes?
Asthma is defined by a positive response to the following question: 
Have you [has your child] had wheezing or whistling in the chest in the past 12 months? 
The environmental questionnaire for the 6-7-year-old age group contained more questions on early 
life exposures as this was completed by the parents of the child. We restricted our analyses to the risk 
factors which had shown associations with either rhinoconjunctivitis, asthma or eczema symptoms in 
the last 12 months in previous analyses at the individual level. Variables included for the younger age 
group (6-7 years) were paracetamol use in the first year of life and in the past 12 months [6], antibiotic 
use in the first year of life [7], breast feeding [8], pets in the home in the first year of life [9], regular 
contact with farm animals in the first year of life and prenatally through maternal contact [10], truck 
traffic in the last 12 months [11], fast food consumption in the last 12 months [12], television viewing 
in the last 12 months [13], parental smoking in the last 12 months [14], open fire cooking [15], birth 
weight [16] and number of siblings [17]. For the older age group (13-14 years), truck traffic [11], fast 
food consumption [12], television viewing [13], parental smoking [14] and paracetamol use [18], all in 
the past 12 months, open fire cooking [15] and number of siblings [17] were included. 
Most of the above risk factors were parameterised as binary variables from “yes/no” questions in the 
environmental questionnaire. The exceptions were: paracetamol use in the past 12 months (at least 
once per month vs. less than once per month), heavy truck traffic (frequently or almost the whole day 
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vs. seldom or never), fast food consumption (once per week or more vs. less than once per week), 
television viewing (at least 1 hour per day vs. less than 1 hour per day), birth weight (less than 2.5 kg 
vs. at least 2.5 kg) and number of siblings (2 or more siblings vs. 1 or no siblings). Full definitions are 
in Table S1, Supporting Material. The highest level of maternal education was recorded as primary, 
secondary, tertiary or missing/not stated.  
Gross National Income (GNI) in 2002 was obtained from the World Bank website [22] where available, 
with gaps filled by the CIA World Factbook [23]. Countries were classified as ‘affluent’ or ‘non-affluent’ 
using a 2001 GNI value of US$9,205 per capita as a cut-off, which separates high-income countries 
from low and middle-income countries [24]. 
Statistical analyses 
Separate analyses were conducted for the two age groups. Centres with fewer than 1,000 individuals 
in an age group were excluded from the analyses for that age group. Each school was required to have 
at least 10 individuals to be included in the analyses for that age group. In addition, a response rate of 
at least 60% was required for children and at least 70% for adolescents for a centre to be included.  
Mixed effect (multilevel) logistic regression models were used for all analyses with random intercepts 
at the 3 highest levels of the four-level hierarchy: individuals, schools, centres and countries (from 
lowest to highest). All analyses additionally adjusted for sex and maternal education as confounders 
at the individual level. 
The potential risk factors for rhinoconjunctivitis symptoms were compared at individual level and at 
school level in a similar way to previous publications on asthma [20] and eczema [21]. The school-level 
risk factors are less prone to reverse causation bias than the individual-level risk factors as a change 
in behaviour of a few people with the disease will not greatly affect the school-level prevalence of that 
risk factor. Thus, similar results at both levels can be interpreted as suggestive evidence against 
reverse causation influencing individual-level associations.  
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For comparison of risk factor associations between the three different diseases, three different 
modelling approaches were used:  
i) Standard outcomes - modelling the three disease outcomes separately but within the 
same sample of children,  
ii) Multimorbid outcomes - modelling each of the different combination of disease outcomes 
(i.e. asthma only, eczema only, rhinoconjunctivitis only, asthma and eczema, asthma and 
rhinoconjunctivitis, eczema and rhinoconjunctivitis, and all three) against those with no 
disease and comparing the resulting risk factor associations, and  
iii) Unimorbid outcomes - comparing individuals with only asthma, only eczema or only 
rhinoconjunctivitis symptoms in the last 12 months and modelling the three combinations 
of disease pairs to evaluate if the risk factors are more associated with one disease than 
another.  
In each of these modelling analyses we checked for collinearity between the risk factors by comparing 
the standard errors in the fully adjusted model (all risk factors and confounders) to those in minimally 
adjusted models (only the risk factor of interest and the confounders).  
Additionally, we ran each model separately for ‘affluent’ and ‘non-affluent’ countries (with the 
exception of the multimorbid outcomes analyses where some of the sample sizes were too small). We 
also tested for an interaction between country affluence and each risk factor individually.
Analyses were conducted using Stata version 15 [25]. 
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Results 
Derivation and characteristics of the sample analysed 
In the age 6-7 analyses there were 75 centres (comprising 221,280 children) that met the standard 
ISAAC inclusion criteria [1] of a minimum of 1,000 children and a response rate of at least 60%. For 
multi-level analysis, 263 schools (1,427 children in total) were excluded due to having fewer than 10 
children and a further 102,990 children excluded for not having data available for all three outcomes 
(asthma, eczema and rhinoconjunctivitis symptoms), confounders (sex and mother’s level of 
education) and all the included risk factors. The remaining 116,863 children, on which these results 
are based (the “synthesis sample”), were from 2,163 schools within 59 centres, in 22 different 
countries (Figure S1, Supporting Material).  
The prevalence of rhinoconjunctivitis symptoms among the 6-7-year-olds included in this analysis was 
8.9%, asthma symptoms was 9.7% and eczema symptoms was 7.3%. The overall prevalence of the 
exposures ranged from 1.8% for current open fire cooking to 80.5% for ever breastfed. These and 
further summary statistics for the synthesis sample are presented in Table 1. 
For the 13-14 year-olds there were 122 centres (comprising 362,048 adolescents) meeting the ISAAC 
criteria [1] of a minimum of 1,000 per centre and a response rate of at least 70%. For multi-level 
analysis, 64 schools (comprising 298 individuals) were excluded due to having fewer than 10 
adolescents. A further 137,314 individuals were excluded for not having data available for all three 
outcomes (asthma, eczema and rhinoconjunctivitis symptoms), confounders (sex and mother’s level 
of education) and all the included risk factors of interest. The remaining “synthesis sample” contained 
224,436 adolescents from 2,037 schools within 97 centres, in 41 different countries (Figure S2, 
Supporting Material).  
The prevalence of rhinoconjunctivitis symptoms among the 13-14-year-olds included in this analysis 
was 14.1%, asthma symptoms was 10.6% and eczema symptoms was 6.2%. The overall prevalence of 
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the exposures ranged from 5.2% for current open fire cooking to 85.7% for watching television at least 
an hour a day. For further details, see Table 1. 
Multi-level models for rhinoconjunctivitis  
Table 2 presents associations at the individual level (within schools) and the area level (between 
schools, within centre) for exposures of interest, adjusted for sex and mother’s educational level 
(“minimally adjusted”) and for each other (“fully adjusted”), as derived from the multi-level model. 
For the 6-7 age group, the strongest mutually adjusted associations with rhinoconjunctivitis at the 
individual level were current paracetamol use (odds ratio=2.02; 95% CI=1.92-2.13) and antibiotics in 
the first year (1.58; 1.51-1.66). These associations were very similar at the school level with odds ratios 
2.04 (1.43-2.89) and 1.39 (1.03-1.88) respectively. However, the weaker child-level association with 
early paracetamol use (1.39;1.32-1.47) was not seen at the school level (0.99; 0.73-1.35). Similarly, a 
modest child-level association with heavy truck traffic (1.17; 1.12-1.22) was inconsistent with the 
inverse relationship at school level (odds ratio 0.92; 0.73-1.16). Low birthweight showed no evidence 
of an association with rhinoconjunctivitis at the individual level (1.04; 0.96-1.13) but at the school level 
the association was strong and significant (2.59; 1.56-4.29). Similarly, a school-level association was 
evident for television viewing (1.45;1.05-2.01) but not for children within schools (0.93; 0.88-0.98). 
In the 13-14 age group, there was a strong association at the individual level with current paracetamol 
use (1.76; 1.71-1.81) which was even stronger at the school-level (3.48; 2.66-4.56). A less strong child-
level association was observed for heavy truck traffic (1.23; 1.20-1.26) which was consistent at the 
school level (1.16; 0.94-1.44) though there was less precision on the latter estimate. Paternal and 
maternal smoking had similar effects at the individual-level but at the school level their associations 
were in opposite directions. For cooking by open fire, the school-level association (2.02;1.39-2.93) was 
much stronger than the child-level association (1.16;1.08-1.26). 
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The precision of estimates from the fully adjusted models and those from the corresponding minimally 
adjusted models (Table 2) were compared and no evidence of collinearity was found.
Comparison of risk factor patterns for rhinoconjunctivitis, asthma and eczema 
Table 3 compares, by age group, the individual-level associations of each exposure with symptoms of 
rhinoconjunctivitis (from Table 2), asthma and eczema (previously published in slightly different 
samples [20,21], but reanalysed here on the same “synthesis sample” as for rhinoconjunctivitis).  
For younger children, the strongest associations in the fully adjusted analyses were similar across all 
three outcomes. They were: current paracetamol use (ORs for rhinoconjunctivitis symptoms 2.02; 
asthma symptoms 2.07; and eczema symptoms 1.46), antibiotic use in the first year of life (1.58; 1.66; 
1.40, respectively), and paracetamol use in the first year of life (1.39; 1.34; 1.29). Heavy truck traffic 
showed a less strong but consistent association with all three outcomes (1.17; 1.19; 1.12). Similarly, 
cat ownership in the first year of life had a consistent direction of association, somewhat stronger with 
asthma (1.22) than with rhinoconjunctivitis (1.09) and eczema (1.10).   
The three diseases differed in their associations with some other risk factors. Exposures showing a 
harmful association with asthma but no statistically significant association with rhinoconjunctivitis and 
eczema were cooking on an open fire and fast food. Low birthweight showed a harmful association 
with asthma (OR=1.15), a marginally statistically significant protective effect with eczema (OR=0.90) 
and no association with rhinoconjunctivitis. Breast feeding was associated with increased risk of 
eczema (1.11), a marginally statistically significant protective association with asthma (OR=0.95) and 
no association with rhinoconjunctivitis. 
Among adolescents, exposures showing consistent associations with all three diseases were current 
paracetamol use (odds ratios for rhinoconjunctivitis 1.76; asthma 1.80; and eczema 1.58), heavy truck 
traffic (1.23; 1.20; 1.31, respectively), cooking on an open fire (1.16; 1.19; 1.49), mother smoking (1.14; 
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1.22; 1.11), and father smoking (1.10; 1.11; 1.15). Weaker associations with fast food were also 
consistent (1.06; 1.07; 1.06) across the three diseases (Table 3). 
Comparison of risk factor patterns in affluent and less affluent countries  
Figures 1A-1C summarise the risk factor-disease associations by age group, stratified by national per 
capita GNI. (Numerical results are shown in Table S2, Supporting Material.) Many of the risk factor-
disease associations are fairly consistent between affluent and non-affluent settings, with most 
differences being within the range expected by chance (interaction p>0.01). In the section below we 
focus upon the most significant inconsistencies (interaction p<0.0001 for one or more diseases). 
For rhinoconjunctivitis among 6-7-year-olds (Figures 1A and 1B), notable differences by national per 
capita GNI are increased risk in non-affluent countries with farm animal contact in infancy (1.19; 1.07-
1.33) and having more than two siblings (1.06; 1.00-1.13), whereas in affluent countries, these 
associations are protective (0.88; 0.75-1.03 and 0.87; 0.81-0.94, respectively). 
For asthma among 6-7-year-olds (Figures 1A and 1B), farm animal exposure in pregnancy showed a 
harmful association in non-affluent countries (1.32; 1.18-1.49) but no significant effect in affluent 
countries (0.98; 0.83-1.14). Breastfeeding ever showed a protective effect in non-affluent countries 
(0.87; 0.81-0.94) but no significant effect in affluent countries (1.02; 0.96-1.10). Cat exposure in 
infancy increased risk of asthma symptoms in both settings but there was evidence of a stronger effect 
in non-affluent (1.36; 1.24-1.49) than affluent countries (1.10; 1.01-1.20). Conversely, current 
paracetamol use elevated asthma risk to a significantly greater extent in affluent (2.36; 2.19-2.56) than 
non-affluent settings (1.90; 1.78-2.02). 
For eczema among 6-7-year-olds (Figures 1A and 1B), early cat exposure was a risk factor in non-
affluent countries (1.23; 1.11-1.36) but not in affluent countries (0.99; 0.90-1.09). Farm animal 
exposure in infancy increased eczema risk in non-affluent (1.25; 1.11-1.40) but not in affluent 
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countries (0.95; 0.80-1.13), and a similar pattern was evident for farm animal exposure in pregnancy. 
Current paracetamol use was more strongly associated with eczema symptoms in affluent (1.65; 1.50-
1.81) than non-affluent settings (1.35; 1.25-1.46), although this heterogeneity (interaction p=0.003) 
was less significant than for asthma. 
Stratifying the 13-14 year-old results in a similar manner (Figure 1C and Table S2), few risk factors 
demonstrate differential effects in affluent and non-affluent countries. For rhinoconjunctivitis, open 
fire cooking increased risk in non-affluent countries (1.20; 1.11-1.30) but not in affluent countries 
(0.82; 0.62-1.07) (interaction p=0.008). Across all three outcomes, current paracetamol use showed a 
harmful effect in both affluent and non-affluent countries but the effect was stronger in affluent 
countries (interaction p<0.0001 for rhinoconjunctivitis, p=0.0009 for asthma, p=0.009 for eczema). 
Multimorbid (combinations of disease) models 
In the 6-7 year-old synthesis sample, 80.1% of the children had no symptoms of any of the three 
outcomes. The proportion of children with only one disease was 14.9% (rhinoconjunctivitis 4.7%, 
asthma 5.8%, eczema 4.4%). The proportions with two diseases was 4.1% (rhinoconjunctivitis and 
asthma 2.1%, rhinoconjunctivitis and eczema 1.1%, and asthma and eczema 0.9%). Just 0.9% of the 
sample had symptoms of all three diseases (Table 1). 
Using models comparing different combinations of disease outcomes to those with no disease (Table 
4), we found that antibiotics in the first year of life showed a stronger effect among individuals with 2 
or 3 diseases. Paracetamol in the first year had similar effects across any combination of the diseases, 
with a slightly stronger effect only noticed with individuals who have all 3 diseases. This was similar 
for current heavy truck traffic. Current paracetamol showed a stronger effect in asthma and 
rhinoconjunctivitis than eczema, as reflected in the combinations of multiple diseases with the 
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strongest effects being in individuals with all three diseases or rhinoconjunctivitis and asthma (Table 
4). 
Among the 13-14 year-old synthesis sample, 76.0% had no symptoms of any of the three outcomes. 
The proportion of adolescents with only one disease was 18.1% (rhinoconjunctivitis 8.8%, asthma 
6.1%, eczema 3.2%). A further 5.0% had symptoms of two of the diseases (rhinoconjunctivitis and 
asthma 2.9%, rhinoconjunctivitis and eczema 1.4% and asthma and eczema 0.7%). Only 0.9% had 
symptoms of all three diseases (Table 1). 
Current paracetamol showed a stronger effect in individuals with more than one disease, with the 
strongest effect in those with all 3 diseases. Open fire cooking showed a stronger effect in all 
combinations that contain eczema (Table 4). 
Importantly, in both age groups, risk factor associations with each disease in the whole population 
(Table 3) persisted among children with only one condition, after exclusion of multimorbid groups 
(Table 4). 
Unimorbid (single disease case-only) models 
Table 5 shows the results of three separate models, each comparing two of the unimorbid outcomes.  
Corresponding results, stratified by per capita GNI, are shown as Table S3 in the Supporting Material. 
Triangle plots appear as Figures S3-S8 in the Supporting Material. An equilateral central triangle 
denotes a risk factor that has a similar strength of effect on all three diseases, the further from 
equilateral the triangle is, the more that risk factor effect differs in strength between diseases. In the 
plots the odds ratios displayed are all greater than or equal to one; they relate to whichever disease 
has the stronger effect (the corner they are closest to compared to the opposite corner). 
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In the 6-7 year-old age group, low birthweight was most strongly associated with asthma and more 
strongly associated with rhinoconjunctivitis than eczema. Early life antibiotic exposure showed a 
similar pattern but to a slightly reduced extent. Being breastfed ever showed a stronger association 
with eczema than both asthma and rhinoconjunctivitis. Owning a cat in the first year of life was most 
strongly associated with asthma but more strongly associated with eczema than rhinoconjunctivitis. 
Some differences were evident between affluent and non-affluent countries (Table S3 and Figure S6). 
Farm animal contact during pregnancy had effects in non-affluent countries which were more 
balanced between the diseases, but in affluent countries the effect was stronger on eczema and 
rhinoconjunctivitis than asthma. In contrast, early cat contact had more balanced effects in affluent 
countries but in non-affluent countries there was a much stronger effect on asthma and eczema than 
rhinoconjunctivitis.  
Among the current exposures for 6-7 year-olds, current paracetamol use was more strongly associated 
with asthma and rhinoconjunctivitis than with eczema. Open fire cooking was more strongly 
associated with both asthma and eczema than rhinoconjunctivitis but the confidence intervals were 
wide. Maternal smoking was more strongly associated with asthma than with eczema or 
rhinoconjunctivitis. Affluent centres showed a stronger effect of open fire cooking on asthma and 
rhinoconjunctivitis, whereas in non-affluent centres the stronger effect was on asthma and eczema. 
Among 13-14 year-olds, similar to the younger children, maternal smoking had a stronger association 
with asthma than with either eczema or rhinoconjunctivitis, and current paracetamol showed a 
stronger association with asthma and rhinoconjunctivitis than with eczema. The biggest difference 
between affluent and non-affluent countries was observed for open fire cooking. In affluent countries, 
there were stronger associations with eczema than with asthma or rhinoconjunctivitis although it is 
important to note that the confidence intervals were exceptionally large due to the rarity of cooking 
on open fires in the affluent centres. 
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Discussion 
Overview of findings 
This is the largest and broadest overview to date of lifestyle and environmental risk factors for 
symptoms of non-infective rhinoconjunctivitis among children. It is the first comprehensive analysis 
of this condition, which models multiple risk factors together to compare their mutually adjusted 
individual-level and population (school)-level associations in a multilevel framework. Due to the 
multiple comparisons made, and the large size of our sample, we concentrate our interpretation upon 
the overall patterns of results and on specific findings with more extreme levels of statistical 
significance. 
Generally, associations with exposures averaged at the school level were similar in direction and 
magnitude to those ascertained at the child level, as we found also for symptoms of asthma and 
eczema. As we have argued elsewhere [20-21] this helps to exclude reverse causation, particularly for 
exposures such as early paracetamol and antibiotic use which may be related to prodromal disease, 
or pets which may be avoided by allergic families. An exception are the results for breastfeeding, 
showing a borderline significant inverse association with asthma symptoms, a significantly positive 
association with eczema symptoms and a null association with rhinoconjunctivitis at the individual 
level (table 3). Nevertheless, the association of breastfeeding with rhinoconjunctivitis at the school 
level is strongly and significantly inverse (table 2), perhaps indicating confounding by socioeconomic 
or other unmeasured characteristics of the school catchment population. This contrasts with the 
pattern of school-level associations of breastfeeding with symptoms of asthma [20] and eczema [21], 
which were weakly positive but non-significant. 
Many of the risk factor associations observed for symptoms of rhinoconjunctivitis were similar to 
those previously reported for symptoms of asthma or eczema in ISAAC Phase Three [6-21]. Since the 
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three diseases cluster together at the individual level, it is possible that associations observed for one 
disease could be influenced by risk factors for other conditions in the triad. An innovative use of ISAAC 
data in this paper is the analysis of rhinoconjunctivitis, asthma and eczema, singly and in combination. 
As expected, we found that associations with multimorbidity (combinations of two or three diseases) 
were stronger than for each disease alone (unimorbidity). However, the relationships of risk factors 
with each disease in the absence of the others were of similar direction and magnitude to the results 
for each condition modelled separately. Thus, multimorbidity is not the sole explanation of the 
common epidemiological patterns across these three diseases.  
For many risk factors, associations were consistent across the three diseases, between the two age 
groups, and between countries with different levels of per capita Gross National Income. This 
similarity of epidemiology strongly suggests that there are common biological mechanisms for these 
three diseases, which operate in both affluent and less affluent settings. The most striking example of 
this in our ISAAC dataset is current paracetamol exposure, which was consistently associated with 
each of the three diseases, within schools and between schools, in both age groups and in richer and 
poorer countries, although somewhat more strongly with rhinoconjunctivitis and asthma than with 
eczema. 
Shared mechanisms do not exclude the possibility of disease-specific pathways, which may differ 
between higher and lower income countries. An example of the latter is the inverse association of 
seasonal rhinoconjunctivitis with number of siblings and childhood exposure to the farm environment. 
This is well established from large epidemiological studies in Europe and confirmed by objective 
markers of allergic sensitisation [26]. This pattern is consistent with our findings for rhinoconjunctivitis 
symptoms in affluent countries but contrasts with the increased risk of these symptoms among 
children from larger families and those exposed to farm animals in poorer countries. 
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Strengths and limitations
ISAAC Phase Three has substantial advantages in terms of large sample sizes drawn from diverse study 
centres worldwide, who adopted standardised methods of data collection. Reliance solely upon 
questionnaires completed by parents (for the 6-7-year-olds) or participants (for the 13-14-year-olds) 
is a limitation, both for definition of disease outcomes and for ascertainment of risk factors. On the 
other hand, the questionnaire methodology maintained high response rates in each centre. 
Misclassification of disease or risk factor information could be non-systematic, leading to weaker 
associations, or systematic, potentially exaggerating or masking associations. A particular concern 
would be individual differences in the threshold for reporting of symptoms, which could exaggerate 
clustering of the three complaints within individual children. This is unlikely to affect risk factor 
associations in our unimorbid analysis, where similarity in the epidemiological patterns for the each 
of the three diseases (in the absence of the others, Table 4) would be biased only if reporting of all 
three diseases were altered by the presence of the risk factor (or conversely, reporting of the common 
risk factor were biased to a similar degree by the presence of each of the three diseases). 
A particular limitation of ISAAC Phase Three is the lack of objective information on allergic 
sensitisation. This was measured by skin prick testing and serum allergen-specific IgE in a separate 
study of more than 50,000 10-11-year-old children in 30 centres from 22 countries (ISAAC Phase Two) 
[3-5,27]. Although (as expected) symptoms of rhinoconjunctivitis, asthma and eczema were more 
common among children with positive skin prick tests, these associations were substantially weaker 
in less affluent settings. The proportion of each disease attributable to skin prick positivity in centres 
from lower-income countries (per capita GNI < USD 9,200 in 2001) was 14% for rhinoconjunctivitis, 
20% for asthma but only 1% for eczema. The corresponding population attributable fractions (PAFs) 
in higher-income countries were 61% for rhinoconjunctivitis, 46% for asthma and 28% for eczema. The 
PARF estimates were very similar when serum allergen-specific IgE was used as the measure of allergic 
sensitisation [4].
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Throughout, ISAAC has focused upon the combination of nasal and conjunctival symptoms (in the 
absence of intercurrent infection) as the most relevant definition of rhinoconjunctivitis because non-
infective rhinitis alone (without itchy eyes) is less strongly associated with skin prick positivity (PAFs 
of 5% in less affluent centres and 10% in more affluent centres) [27]. More recent studies, among 
adolescents [28] and adults [29] have confirmed a stronger association of allergic sensitisation with 
rhinoconjunctivitis than with rhinitis alone. 
A shared non-allergic mechanism for “atopic diseases”? 
In recent decades, two models of multimorbidity have been proposed to explain the occurrence of 
two or more “atopic diseases” (asthma, rhinitis and eczema, sometimes extended also to food allergy). 
The term “united airway disease” has been proposed for the coexistence of asthma and rhinitis in the 
same patient at the same time [30-32]. The concept of the “atopic march” applies to the sequential 
development of eczema, asthma and rhinitis (usually in that order) through childhood and 
adolescence [33,34]. Discussion of both concepts has tended to focus upon IgE-mediated allergic 
mechanisms and Th2-immune inflammatory pathways as an explanation for concurrent and 
longitudinal clustering of the three diseases.  
However, it is recognised that several distinct pathways and mechanisms are likely to be involved in 
the atopic march, some of them common and some disease-specific [34]. Non-allergic airway 
inflammation, defects of mucosal defence, and exogenous cofactors (including microbes, pollutants 
and smoking) have been proposed as “treatable traits” underlying united airway disease [32], in 
addition to the close association of both asthma and rhinitis with IgE sensitisation, particularly to 
multiple allergens [35]. 
Genome-wide association studies have shown a mixture of common and disease-specific signals for 
asthma, hay fever and eczema [36] illustrated by triangle plots derived from unimorbid case-only 
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comparisons similar to those we have shown in Table 5 and Figures S3-S8. Filaggrin (FLG) variants are 
specifically associated with eczema, whereas other genome-wide significant loci such as IL6R show 
almost perfect symmetry in association with each of the three diseases. A bioinformatics (data-mining) 
analysis of protein interactions found that asthma, rhinitis and eczema shared more associated 
proteins than would be expected by chance and identified 15 pathways potentially involved in the 
multimorbidity of asthma, rhinitis and eczema, although many of these are related to Th2-immune 
signalling pathways [37]. 
Epidemiological evidence for non-allergic mechanisms underlying coexistence of asthma, rhinitis and 
eczema emerges from the collaborative analysis of European birth cohorts by the MeDALL consortium 
[38]. Among over 8,000 children followed from birth to 4 and 8 years of age, IgE sensitisation to 
common food and aero-allergens at age 4 years accounted for only 38% of the co-occurrence of two 
or more conditions (asthma, rhinitis and eczema) at age 8 years. In relative terms, the strength of the 
association among the three diseases was higher in non-sensitised children, although the excess 
comorbidity was greater among those who were sensitised, due to a higher baseline risk of disease. 
Among the sensitised children, about a quarter of the observed comorbidity was not due to chance, 
whereas among non-sensitised children the non-chance proportion was more than half at age 8 years. 
Comorbidity at age 4 years was strongly predictive of comorbidity at age 8 years. All these 
observations led the MeDALL investigators to propose “a new vision of multimorbidity independent 
of IgE sensitisation” [39], which would be entirely consistent with our observations of common 
epidemiological patterns for symptoms of rhinoconjunctivitis, asthma and eczema in two age groups 
of children in both affluent and non-affluent countries worldwide. 
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Conclusions 
Most of the environmental and lifestyle correlates of rhinoconjunctivitis, asthma and eczema in 
childhood display similarity across the three conditions, even in less affluent settings where allergic 
sensitisation (as conventionally defined) is less likely to explain the concordant epidemiological 
patterns. This supports the view that mechanisms other than IgE-mediated tissue inflammation may 
contribute a substantial proportion of the clustering of these “atopic diseases” within individuals 
(concurrently and sequentially) and at the population level. 
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Figure legends 
Figures 1A, 1B, 1C
Mutually adjusted odds ratios and 95% confidence intervals for individual-level associations between 
risk factors and each of the three diseases, in affluent countries and non-affluent countries. 
1A 6-7-year-olds, early exposures 
1B 6-7-year-olds, current exposures 
1C 13-14-year-olds, current exposures 
Footnotes (common to all 3 figures)
Results from mixed logistic regression models with random intercepts at the school, centre and 
country levels. Adjusted for sex. Mother’s level of education and all other variables shown for the 
same age group. Based on the synthesis sample as shown in table 3, stratified by country-level 
affluence. 
Results for affluent countries shown as diamonds (N = 41,831 aged 6-7; N = 46,932 aged 13-14). 
Results for non-affluent countries shown as circles (N = 75,032 aged 6-7; N = 177,504 aged 13-14). 
Results for rhinoconjunctivitis symptoms (R) shown in yellow. 
Results for asthma symptoms (A) shown in blue. 
Results for eczema symptoms (E) shown in red. 
Data points are tabulated in supplementary table S2.
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Table 1: Summary statistics for variables and their prevalence in subjects who had data present for the 3 outcomes, the confounders sex and maternal education level 
and all other exposures of interest in the table (the “synthesis sample”). 
Variable 
Type Variable 
Age 6-7 years (n=116,863) Age 13-14 years (n=224,436) 
Individual Level Centre Level Prevalence (%) Quartiles Individual Level Centre Level Prevalence (%) Quartiles 
Prevalence (%) Min Q1 Med Q3 Max Prevalence (%) Min Q1 Med Q3 Max 
Outcome 
Rhinoconjunctivitis in the past 12 months 8.9 0.9 3.7 7.5 12.2 25.2  14.1 1.2 8.8 13.2 18.5 31.7 
Asthma symptoms in the past 12 months 9.7 2.5 5.4 9.0 13.2 29.7  10.6 0.7 6.1 9.8 14.4 32.4 
Eczema symptoms in the past 12 months 7.3 0.6 2.5 6.0 10.9 18.9  6.2 0.1 3.0 4.7 8.0 23.8 
Multiple 
outcome 
No symptoms 80.1 62.2 74.1 80.1 89.0 95.0  76.0 51.8 69.6 75.8 83.5 98.2 
Rhinoconjunctivitis only 4.7 0.3 2.2 3.6 5.2 16.5  8.8 1.1 5.0 8.4 11.1 22.4 
Asthma only 5.8 1.7 3.6 5.0 7.4 26.1  6.1 0.6 3.7 5.5 8.0 19.6 
Eczema only 4.4 0.6 1.8 3.2 5.5 11.4  3.2 0.0 1.6 2.5 4.1 13.4 
Rhinoconjunctivitis and Asthma 2.1 0.2 0.8 2.0 3.3 4.9  2.9 0.0 1.4 2.6 4.0 10.3 
Rhinoconjunctivitis and Eczema 1.1 0.0 0.3 0.8 1.6 4.3  1.4 0.0 0.5 0.9 1.6 8.0 
Asthma and Eczema 0.9 0.0 0.3 0.6 1.3 3.9  0.7 0.0 0.2 0.5 1.0 2.9 
Symptoms of all three 0.9 0.0 0.2 0.8 1.4 3.3  0.9 0.0 0.3 0.8 1.2 4.1 
Early Life 
Exposure 
Low birthweight 7.7 0.0 5.2 6.2 9.4 39.4  NA NA NA NA NA NA 
Breastfed ever 80.5 29.2 79.3 84.7 91.2 97.0  NA NA NA NA NA NA 
Farm animals (prenatal) 7.7 0.7 4.5 7.5 10.7 24.2  NA NA NA NA NA NA 
Farm animals (1st year) 9.3 1.9 6.2 9.3 13.5 24.9  NA NA NA NA NA NA 
Cat (1st year) 10.9 1.2 4.9 8.3 11.9 53.8  NA NA NA NA NA NA 
Dog (1st year) 19.8 0.7 10.6 18.2 27.6 46.3  NA NA NA NA NA NA 
Paracetamol (1st year) 66.1 8.6 59.0 68.1 82.7 93.9  NA NA NA NA NA NA 
Antibiotics (1st year) 55.6 18.8 52.0 57.8 62.3 77.7  NA NA NA NA NA NA 
Current 
Exposure 
2 or more siblings 34.7 12.4 21.9 31.8 45.3 83.1  53.9 3.9 37.9 57.6 73.3 100.0 
Heavy truck traffic (past 12 months) 37.9 6.3 32.1 37.8 43.8 67.4  39.5 15.2 32.3 38.0 45.0 90.9 
Fast food (past 12 months) 39.6 9.3 20.4 42.4 54.3 98.1  53.6 6.1 42.7 53.7 66.4 98.3 
Television (past 12 months) 80.1 40.1 72.9 82.2 89.1 95.3  85.7 42.9 80.9 90.0 93.2 98.0 
Paternal tobacco (past 12 months) 31.7 3.2 19.9 28.9 43.6 55.3  38.5 2.7 23.9 36.4 46.4 94.1 
Maternal tobacco (past 12 months) 16.3 0.0 1.6 12.6 24.5 46.6  18.3 0.4 2.7 14.1 28.9 93.7 
Paracetamol (past 12 months) 17.8 0.0 9.9 15.7 23.9 65.3  26.7 0.0 18.4 28.6 34.7 66.0 
Open fire cooking 1.8 0.0 0.3 1.1 2.0 44.8  5.2 0.0 0.6 1.3 4.1 86.1 
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Table 2. Individual-level (within school) and school-level (between school) effects of exposures on rhinoconjunctivitis symptoms using the synthesis sampleA. Mixed logistic 
regression models with random intercepts at the school, centre and country levels.
Age group Exposures of Interest 
Minimally adjusted modelB Fully adjusted modelC
Individual-level School-level Individual-level School-level
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
6-7 years 
(n=116,863) 
Low birthweight 1.11 (1.02, 1.20) 3.03 (1.88, 4.88) 1.04 (0.96, 1.13) 2.59 (1.56, 4.29) 
Breastfed ever 0.97 (0.92, 1.02) 0.52 (0.37, 0.73) 1.00 (0.95, 1.06) 0.62 (0.44, 0.88)
Farm animals (prenatal) 1.36 (1.27, 1.46) 1.56 (1.10, 2.22) 1.18 (1.07, 1.30) 1.16 (0.61, 2.20) 
Farm animals (1st year) 1.30 (1.21, 1.39) 1.55 (1.11, 2.16) 1.07 (0.98, 1.17) 1.19 (0.65, 2.18) 
Cat (1st year) 1.19 (1.11, 1.27) 1.36 (0.94, 1.97) 1.09 (1.01, 1.16) 1.10 (0.72, 1.68)
Dog (1st year) 1.16 (1.10, 1.21) 1.21 (0.89, 1.63) 1.07 (1.01, 1.12) 0.94 (0.67, 1.31) 
Paracetamol (1st year) 1.80 (1.71, 1.89) 1.32 (1.01, 1.75) 1.39 (1.32, 1.47) 0.99 (0.73, 1.35) 
Antibiotics (1st year) 1.84 (1.75, 1.92) 1.45 (1.09, 1.91) 1.58 (1.51, 1.66) 1.39 (1.03, 1.88)
2 or more siblings 0.99 (0.95, 1.04) 1.04 (0.83, 1.30) 0.98 (0.94, 1.03) 0.88 (0.69, 1.12) 
Heavy truck traffic (current) 1.25 (1.20, 1.31) 1.12 (0.90, 1.40) 1.17 (1.12, 1.22) 0.92 (0.73, 1.16) 
Fast food (current) 1.04 (0.99, 1.09) 1.13 (0.89, 1.42) 0.99 (0.94, 1.03) 1.04 (0.82, 1.32)
Television (current) 0.98 (0.92, 1.03) 1.59 (1.18, 2.14) 0.93 (0.88, 0.98) 1.45 (1.05, 2.01) 
Paternal tobacco (current) 1.11 (1.06, 1.16) 1.34 (1.03, 1.74) 1.07 (1.02, 1.12) 0.86 (0.63, 1.19) 
Maternal tobacco (current) 1.12 (1.06, 1.19) 1.67 (1.25, 2.23) 1.05 (0.99, 1.11) 1.39 (0.98, 1.96)
Paracetamol (current) 2.30 (2.18, 2.42) 2.30 (1.66, 3.20) 2.02 (1.92, 2.13) 2.04 (1.43, 2.89) 
Open fire cooking (current) 1.03 (0.86, 1.23) 2.21 (1.16, 4.22) 0.99 (0.82, 1.19) 1.85 (0.92, 3.71) 
13-14 years 
(n=224,436) 
2 or more siblings 1.05 (1.02, 1.08) 1.02 (0.83, 1.25) 1.04 (1.01, 1.07) 0.93 (0.75, 1.15)
Heavy truck traffic (current) 1.27 (1.24, 1.30) 1.35 (1.09, 1.67) 1.23 (1.20, 1.26) 1.16 (0.94, 1.44) 
Fast food (current) 1.10 (1.07, 1.13) 1.31 (1.07, 1.61) 1.06 (1.03, 1.08) 1.24 (1.02, 1.51) 
Television (current) 1.04 (1.00, 1.08) 1.35 (0.97, 1.88) 1.01 (0.97, 1.05) 1.20 (0.86, 1.68)
Paternal tobacco (current) 1.16 (1.13, 1.19) 1.08 (0.84, 1.40) 1.10 (1.07, 1.13) 0.75 (0.55, 1.00) 
Maternal tobacco (current) 1.21 (1.17, 1.25) 1.46 (1.08, 1.97) 1.14 (1.10, 1.17) 1.56 (1.12, 2.18) 
Paracetamol (current) 1.80 (1.75, 1.85) 3.52 (2.69, 4.60) 1.76 (1.71, 1.81) 3.48 (2.66, 4.56)
Open fire cooking (current) 1.16 (1.08, 1.25) 1.73 (1.19, 2.49) 1.16 (1.08, 1.26) 2.02 (1.39, 2.93) 
ASynthesis sample contains individuals with data present for all 3 outcomes, sex, maternal education and all exposures of interest.  
BAdjusted for sex and mothers level of education. 
CAdjusted for sex, mothers level of education and all other variables in the table (within age group). 
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Table 3. Single outcome models of fully adjustedA, individual-level (within school) effects of exposures using the synthesis sampleB. Mixed logistic regression models 
with random intercepts at the school, centre and country levels.
Age group Exposures of Interest 
Fully adjusted modelA
Rhinoconjunctivitis 
symptoms 
Asthma
symptoms 
Eczema
symptoms 
OR (95% CI) OR (95% CI) OR (95% CI) 
6-7 years 
n=116,863 
Low birthweight 1.04 (0.96, 1.13) 1.15 (1.07, 1.25) 0.90 (0.82, 0.99)
Breastfed ever 1.00 (0.95, 1.06) 0.95 (0.90, 1.00) 1.11 (1.04, 1.17) 
Farm animals (prenatal) 1.18 (1.07, 1.30) 1.19 (1.08, 1.30) 1.12 (1.01, 1.24) 
Farm animals (1st year) 1.07 (0.98, 1.17) 0.98 (0.89, 1.06) 1.13 (1.03, 1.25)
Cat (1st year) 1.09 (1.01, 1.16) 1.22 (1.14, 1.30) 1.10 (1.02, 1.18) 
Dog (1st year) 1.07 (1.01, 1.12) 1.03 (0.98, 1.08) 1.06 (1.00, 1.12) 
Paracetamol (1st year) 1.39 (1.32, 1.47) 1.34 (1.27, 1.41) 1.29 (1.22, 1.37)
Antibiotics (1st year) 1.58 (1.51, 1.66) 1.66 (1.59, 1.74) 1.40 (1.33, 1.47) 
2 or more siblings 0.98 (0.94, 1.03) 0.97 (0.92, 1.01) 0.94 (0.90, 0.99) 
Heavy truck traffic (current) 1.17 (1.12, 1.22) 1.19 (1.14, 1.24) 1.12 (1.06, 1.17)
Fast food (current) 0.99 (0.94, 1.03) 1.08 (1.04, 1.13) 0.99 (0.94, 1.05) 
Television (current) 0.93 (0.88, 0.98) 1.05 (0.99, 1.11) 0.96 (0.90, 1.02) 
Paternal tobacco (current) 1.07 (1.02, 1.12) 1.10 (1.05, 1.16) 1.04 (0.99, 1.10)
Maternal tobacco (current) 1.05 (0.99, 1.11) 1.20 (1.14, 1.27) 1.05 (0.99, 1.12) 
Paracetamol (current) 2.02 (1.92, 2.13) 2.07 (1.97, 2.17) 1.46 (1.38, 1.55) 
Open fire cooking (current) 0.99 (0.82, 1.19) 1.21 (1.04, 1.42) 1.14 (0.96, 1.35)
13-14 years 
n=224,436 
2 or more siblings 1.04 (1.01, 1.07) 1.02 (0.99, 1.06) 1.08 (1.04, 1.12) 
Heavy truck traffic (current) 1.23 (1.20, 1.26) 1.20 (1.16, 1.23) 1.31 (1.26, 1.36) 
Fast food (current) 1.06 (1.03, 1.08) 1.07 (1.04, 1.10) 1.06 (1.02, 1.10)
Television (current) 1.01 (0.97, 1.05) 1.02 (0.97, 1.07) 1.07 (1.01, 1.14) 
Paternal tobacco (current) 1.10 (1.07, 1.13) 1.11 (1.07, 1.14) 1.15 (1.11, 1.20) 
Maternal tobacco (current) 1.14 (1.10, 1.17) 1.22 (1.18, 1.27) 1.11 (1.06, 1.17)
Paracetamol (current) 1.76 (1.71, 1.81) 1.80 (1.75, 1.86) 1.58 (1.52, 1.65) 
Open fire cooking (current) 1.16 (1.08, 1.26) 1.19 (1.10, 1.30) 1.49 (1.34, 1.65) 
AAdjusted for sex, mothers level of education and for all other variables in the table (within age group). 
BSynthesis sample contains individuals with data present for all 3 outcomes, sex, maternal education and all exposures of interest. 
----- Risk factors for rhinoconjunctivitis, asthma and eczema in ISAAC Phase Three -----
28 
Table 4: Multi outcome models of fully adjustedA within school effects of exposures compared to a reference group with no disease. Mixed logistic regression models 
with random intercepts at the school, centre and country levels.
Rhinoconjunctivitis 
only Asthma only Eczema only 
Rhinoconjunctivitis 
and Asthma 
Rhinoconjunctivitis 
and Eczema 
Asthma and 
Eczema 
Rhinoconjunctivitis, 
Asthma and Eczema 
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Age 6-7 years Reference group with no disease, n0=93,554 
Exposures of Interest n1=5,508 n1=6,720 n1=5,099 n1=2,503 n1=1,310 n1=1,074 n1=1,095 
Low birthweight 0.98 (0.88, 1.10) 1.16 (1.05, 1.27) 0.85 (0.75, 0.96) 1.14 (0.98, 1.33) 0.96 (0.76, 1.20) 0.90 (0.70, 1.16) 1.14 (0.91, 1.44)
Breastfed ever 0.98 (0.91, 1.05) 0.93 (0.87, 1.00) 1.12 (1.03, 1.21) 0.96 (0.86, 1.06) 1.10 (0.95, 1.28) 0.98 (0.84, 1.15) 1.12 (0.96, 1.32) 
Farm animals (prenatal) 1.17 (1.03, 1.34) 1.14 (1.01, 1.28) 1.06 (0.93, 1.22) 1.22 (1.01, 1.47) 1.07 (0.84, 1.37) 1.19 (0.89, 1.58) 1.56 (1.20, 2.03)
Farm animals (1st year) 1.11 (0.99, 1.25) 1.03 (0.92, 1.15) 1.17 (1.03, 1.32) 0.97 (0.82, 1.16) 1.40 (1.13, 1.74) 1.04 (0.80, 1.35) 0.86 (0.66, 1.12) 
Cat (1st year) 0.97 (0.88, 1.07) 1.21 (1.12, 1.31) 1.08 (0.99, 1.18) 1.29 (1.14, 1.47) 1.19 (1.00, 1.42) 1.06 (0.89, 1.27) 1.16 (0.97, 1.39)
Dog (1st year) 1.07 (1.00, 1.15) 1.01 (0.94, 1.08) 1.07 (1.00, 1.15) 1.08 (0.98, 1.20) 1.05 (0.92, 1.20) 0.99 (0.86, 1.15) 1.14 (0.99, 1.32) 
Paracetamol (1st year) 1.38 (1.29, 1.48) 1.32 (1.24, 1.41) 1.26 (1.17, 1.35) 1.45 (1.30, 1.62) 1.49 (1.29, 1.72) 1.35 (1.14, 1.60) 1.82 (1.52, 2.18)
Antibiotics (1st year) 1.44 (1.36, 1.54) 1.56 (1.47, 1.65) 1.25 (1.17, 1.33) 1.95 (1.77, 2.15) 1.82 (1.60, 2.07) 2.13 (1.84, 2.47) 2.37 (2.03, 2.76) 
2 or more siblings 0.98 (0.92, 1.04) 0.96 (0.90, 1.01) 0.94 (0.88, 1.00) 0.98 (0.90, 1.08) 0.91 (0.81, 1.03) 0.88 (0.77, 1.01) 0.99 (0.86, 1.13)
Heavy truck traffic (current) 1.13 (1.06, 1.20) 1.18 (1.12, 1.24) 1.08 (1.01, 1.15) 1.19 (1.09, 1.29) 1.15 (1.02, 1.29) 1.11 (0.98, 1.26) 1.50 (1.32, 1.71) 
Fast food (current) 0.96 (0.90, 1.02) 1.08 (1.02, 1.15) 0.96 (0.90, 1.03) 1.06 (0.97, 1.16) 1.01 (0.89, 1.14) 1.21 (1.05, 1.38) 0.98 (0.86, 1.13)
Television (current) 0.91 (0.85, 0.98) 1.07 (0.99, 1.15) 0.97 (0.90, 1.05) 1.02 (0.91, 1.14) 0.85 (0.73, 0.99) 1.05 (0.88, 1.25) 0.95 (0.80, 1.12) 
Paternal tobacco (current) 1.05 (0.98, 1.12) 1.08 (1.02, 1.15) 1.02 (0.96, 1.10) 1.12 (1.03, 1.23) 0.93 (0.82, 1.06) 1.12 (0.97, 1.29) 1.22 (1.06, 1.40)
Maternal tobacco (current) 1.02 (0.94, 1.11) 1.24 (1.16, 1.33) 1.05 (0.97, 1.14) 1.21 (1.09, 1.36) 1.11 (0.94, 1.30) 1.30 (1.11, 1.53) 1.05 (0.89, 1.24) 
Paracetamol (current) 1.90 (1.77, 2.04) 1.96 (1.84, 2.08) 1.34 (1.24, 1.45) 2.86 (2.59, 3.15) 1.91 (1.66, 2.19) 2.17 (1.88, 2.51) 2.92 (2.53, 3.37)
Open fire cooking (current) 0.97 (0.75, 1.25) 1.28 (1.07, 1.55) 1.18 (0.96, 1.45) 1.17 (0.83, 1.67) 1.09 (0.70, 1.72) 1.21 (0.77, 1.91) 0.77 (0.43, 1.39) 
Age 13-14 years Reference group with no disease, n0=170,542
Exposures of Interest n1=19,858 n1=13,585 n1=7,104 n1=6,557 n1=3,219 n1=1,554 n1=2,017
2 or more siblings 1.02 (0.98, 1.06) 1.01 (0.97, 1.05) 1.06 (1.00, 1.12) 1.05 (0.99, 1.11) 1.18 (1.09, 1.29) 1.06 (0.95, 1.19) 1.12 (1.01, 1.24) 
Heavy truck traffic (current) 1.19 (1.16, 1.23) 1.14 (1.09, 1.18) 1.26 (1.20, 1.33) 1.30 (1.23, 1.37) 1.44 (1.34, 1.55) 1.47 (1.33, 1.64) 1.56 (1.42, 1.71)
Fast food (current) 1.04 (1.01, 1.08) 1.06 (1.02, 1.10) 1.06 (1.00, 1.12) 1.13 (1.07, 1.19) 1.12 (1.04, 1.21) 1.13 (1.01, 1.26) 1.13 (1.02, 1.24) 
Television (current) 1.03 (0.98, 1.08) 1.08 (1.02, 1.15) 1.09 (1.01, 1.19) 0.97 (0.89, 1.06) 1.23 (1.08, 1.41) 1.21 (1.01, 1.46) 0.80 (0.69, 0.92)
Paternal tobacco (current) 1.08 (1.04, 1.11) 1.10 (1.05, 1.14) 1.13 (1.07, 1.19) 1.14 (1.07, 1.20) 1.22 (1.13, 1.32) 1.16 (1.04, 1.30) 1.26 (1.14, 1.39) 
Maternal tobacco (current) 1.09 (1.05, 1.14) 1.20 (1.15, 1.26) 1.07 (0.99, 1.14) 1.27 (1.19, 1.35) 1.19 (1.08, 1.31) 1.22 (1.06, 1.39) 1.32 (1.18, 1.49)
Paracetamol (current) 1.62 (1.56, 1.68) 1.69 (1.62, 1.76) 1.36 (1.29, 1.44) 2.34 (2.21, 2.47) 2.16 (2.00, 2.34) 2.12 (1.89, 2.36) 2.98 (2.71, 3.29) 
Open fire cooking (current) 1.15 (1.05, 1.27) 1.12 (1.01, 1.25) 1.33 (1.15, 1.53) 1.09 (0.92, 1.28) 1.50 (1.22, 1.84) 1.93 (1.49, 2.50) 2.22 (1.76, 2.81)
AAdjusted for sex, mother's level of education and all other variables in the table for that age group. 
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Table 5: Fully adjustedA unimorbid two-way models. Mixed logistic regression models with random intercepts at the school, centre and country levels.
Age 
group Exposures of Interest 
Asthma v Eczema Asthma v Rhinoconjunctivitis Rhinoconjunctivitis v Eczema
n=11,819 n=12,228 n=10,607 
OR (95% CI) OR (95% CI) OR (95% CI)
6-7 years 
Low birthweight 1.40 (1.19, 1.64) 1.16 (0.99, 1.35) 1.11 (0.94, 1.32)
Breastfed ever 0.85 (0.76, 0.94) 0.94 (0.85, 1.05) 0.89 (0.80, 1.00) 
Farm animals (prenatal) 1.03 (0.85, 1.23) 0.99 (0.82, 1.18) 1.04 (0.86, 1.26)
Farm animals (1st year) 0.90 (0.76, 1.06) 0.89 (0.75, 1.05) 0.98 (0.83, 1.17)
Cat (1st year) 1.12 (0.99, 1.26) 1.27 (1.11, 1.44) 0.83 (0.73, 0.96) 
Dog (1st year) 0.94 (0.85, 1.04) 0.97 (0.87, 1.07) 0.95 (0.86, 1.05)
Paracetamol (1st year) 1.05 (0.95, 1.16) 0.96 (0.86, 1.06) 1.07 (0.96, 1.19)
Antibiotics (1st year) 1.26 (1.16, 1.38) 1.12 (1.03, 1.23) 1.14 (1.03, 1.25) 
2 or more siblings 1.01 (0.93, 1.10) 0.99 (0.90, 1.08) 1.03 (0.94, 1.13)
Heavy truck traffic (current) 1.08 (1.00, 1.17) 1.05 (0.97, 1.14) 1.06 (0.97, 1.16)
Fast food (current) 1.12 (1.02, 1.22) 1.12 (1.03, 1.23) 1.00 (0.91, 1.10) 
Television (current) 1.13 (1.01, 1.26) 1.16 (1.04, 1.29) 0.92 (0.82, 1.03)
Paternal tobacco (current) 1.03 (0.94, 1.12) 1.03 (0.94, 1.13) 1.02 (0.92, 1.12)
Maternal tobacco (current) 1.16 (1.04, 1.29) 1.21 (1.08, 1.35) 0.94 (0.84, 1.07) 
Paracetamol (current) 1.45 (1.31, 1.60) 1.03 (0.93, 1.14) 1.48 (1.32, 1.65)
Open fire cooking (current) 1.02 (0.77, 1.35) 1.32 (0.95, 1.83) 0.72 (0.51, 1.01)
Age 
group Exposures of Interest 
Asthma v Eczema Asthma v Rhinoconjunctivitis Rhinoconjunctivitis v Eczema 
n=20,689 n=33,443 n=26,962
OR (95% CI) OR (95% CI) OR (95% CI)
13-14 
years 
2 or more siblings 0.94 (0.87, 1.01) 0.99 (0.94, 1.05) 0.96 (0.90, 1.03) 
Heavy truck traffic (current) 0.92 (0.86, 0.99) 0.97 (0.92, 1.02) 0.93 (0.87, 0.98)
Fast food (current) 1.01 (0.94, 1.08) 0.99 (0.94, 1.04) 1.00 (0.94, 1.06)
Television (current) 0.98 (0.88, 1.09) 1.06 (0.98, 1.15) 0.96 (0.87, 1.06) 
Paternal tobacco (current) 0.96 (0.89, 1.03) 1.01 (0.96, 1.06) 0.96 (0.90, 1.03)
Maternal tobacco (current) 1.15 (1.06, 1.26) 1.13 (1.06, 1.21) 1.02 (0.94, 1.11)
Paracetamol (current) 1.17 (1.09, 1.26) 1.02 (0.97, 1.08) 1.16 (1.09, 1.24) 
Open fire cooking (current) 0.89 (0.74, 1.06) 1.05 (0.91, 1.21) 0.80 (0.68, 0.95)
AAdjusted for sex, mother's level of education and all other variables in the table for that age group. 
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Figures 1A, 1B, 1C
Mutually adjusted odds ratios and 95% confidence intervals for individual-level associations 
between risk factors and each of the three diseases, in affluent countries and non-affluent countries. 
1A: aged 6-7, early exposures;  1B: aged 6-7, current exposures;  1C: aged 13-14, current exposures. 
Footnotes (common to all 3 figures)
Results from mixed logistic regression models with random intercepts at the school, centre and 
country levels. Adjusted for sex. Mother’s level of education and all other variables shown for the 
same age group. Based on the synthesis sample as shown in table 3, stratified by country-level 
affluence. 
Results for affluent countries shown as diamonds (N = 41,831 aged 6-7; N = 46,932 aged 13-14). 
Results for non-affluent countries shown as circles (N = 75,032 aged 6-7; N = 177,504 aged 13-14). 
Results for rhinoconjunctivitis symptoms (R) shown in yellow. 
Results for asthma symptoms (A) shown in blue. 
Results for eczema symptoms (E) shown in red. 
Data points are tabulated in supplementary table S2.
----- Risk factors for rhinoconjunctivitis, asthma and eczema in ISAAC Phase Three -----
31 
Legend for supporting information
Table S1: Risk factor definitions. 
Table S2: Single outcome models of fully adjusted within school effects of exposures using the synthesis sample, stratified by country-level affluence. Mixed logistic 
regression models with random intercepts at the school, centre and country levels. 
Table S3: Fully adjusted unimorbid two-way models split by country affluence. Mixed logistic regression models with random intercepts at the school, centre and country 
levels. 
Figure S1. Synthesis sample data flowchart, age 6-7 years. 
Figure S2. Synthesis sample data flowchart, age 13-14 years. 
Figure S3. Triangular graphs showing unimorbid two-way comparisons of early life risk factor effects for 6-7-year-old children. 
Figure S4. Triangular graphs showing unimorbid two-way comparisons of current risk factor effects for 6-7-year-old children. 
Figure S5. Triangular graphs showing unimorbid two-way comparisons of current risk factor effects for 13-14-year-old adolescents. 
Figure S6. Triangular graphs showing unimorbid two-way comparisons of effects of early life risk factors (during first year of life) for 6-7-year-old children in affluent and 
non-affluent countries. 
Figure S7. Triangular graphs showing unimorbid two-way comparisons of effects of current risk factors (from the last 12 months) for 6-7-year-old children in affluent and 
non-affluent countries. 
Figure S8. Triangular graphs showing unimorbid two-way comparisons of effects of current risk factors for 13-14-year-old adolescents in affluent and non-affluent countries.
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SUPPORTING MATERIAL 
Table S1: Risk factor definitions. 
Table S2: Single outcome models of fully adjusted within school effects of exposures using the synthesis sample, stratified by country-level affluence. Mixed logistic 
regression models with random intercepts at the school, centre and country levels. 
Table S3: Fully adjusted unimorbid two-way models split by country affluence. Mixed logistic regression models with random intercepts at the school, centre and 
country levels. 
Figure S1. Synthesis sample data flowchart, age 6-7 years. 
Figure S2. Synthesis sample data flowchart, age 13-14 years. 
Figure S3. Triangular graphs showing unimorbid two-way comparisons of early life risk factor effects for 6-7-year-old children.
Figure S4. Triangular graphs showing unimorbid two-way comparisons of current risk factor effects for 6-7-year-old children. 
Figure S5. Triangular graphs showing unimorbid two-way comparisons of current risk factor effects for 13-14-year-old adolescents. 
Figure S6. Triangular graphs showing unimorbid two-way comparisons of effects of early life risk factors for 6-7-year-old children in affluent and non-affluent countries. 
Figure S7. Triangular graphs showing unimorbid two-way comparisons of effects of current risk factors for 6-7-year-old children in affluent and non-affluent countries. 
Figure S8. Triangular graphs showing unimorbid two-way comparisons of effects of current risk factors for 13-14-year-old adolescents in affluent and non-affluent 
countries. 
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Table S1: Risk factor definitions 
Risk Factors for ages 6-7 Question (asked to parent) Positive Response
Low birthweight What was the weight of your child when he / she was born? Less than 2.5kg 
Breastfed ever Was your child breastfed? Yes 
Farm animals (prenatal) Has the child’s mother had regular (at least once a week) contact with farm animals (e.g. cattle, pigs, goats, sheep or poultry) while being pregnant with this child? Yes 
Farm animals (1st year) In your child’s first year of life, did he / she have regular (at least once a week) contact with farm animals (e.g. cattle, pigs, goats, sheep or poultry)? Yes 
Cat (1st year) Did you have a cat in your home during the first year of your child’s life? Yes 
Dog (1st year) Did you have a dog in your home during the first year of your child’s life? Yes 
Paracetamol (1st year) In the first 12 months of your child’s life, did you usually give paracetamol for fever? Yes 
Antibiotics (1st year) In the first 12 months of your child’s life, did your child have any antibiotics? Yes 
2 or more siblings How many older and younger brothers and sisters does your child have? Total of 2 or more 
Heavy truck traffic (current) How often do trucks pass through the street where you live, on weekdays? Frequently or almost the whole day 
Fast food (current) In the past 12 months, how often, on average did your child eat fast food / burgers? At least once a week 
Television (current) During a normal week, how many hours a day (24 hours) does your child watch television? At least one hour per day 
Paternal tobacco (current) Does your child’s father (or male guardian) smoke cigarettes? Yes 
Maternal tobacco (current) Does your child’s mother (or female guardian) smoke cigarettes? Yes 
Paracetamol (current) In the past 12 months, how often, on average, have you given your child paracetamol? At least once per month 
Open fire cooking (current) In your house, what fuels are usually used for cooking? Electricity, gas, open fires, other  Any that include open fires 
Risk Factors for ages 13-14 Question (asked to child) Positive Response
2 or more siblings How many older and younger brothers and sisters do you have?  Total of 2 or more 
Heavy truck traffic (current) How often do trucks pass through the street where you live, on weekdays? Frequently or almost the whole day 
Fast food (current) In the past 12 months, how often, on average did you eat fast food / burgers? At least once a week 
Television (current) During a normal week, how many hours a day (24 hours) do you watch television? At least one hour per day 
Paternal tobacco (current) Does your father (or male guardian) smoke cigarettes? Yes 
Maternal tobacco (current) Does your mother (or female guardian) smoke cigarettes? Yes 
Paracetamol (current) In the past 12 months, how often, on average, have you taken paracetamol? At least once per month 
Open fire cooking (current) In your house, what fuels are usually used for cooking? Electricity, gas, open fires, other  Any that include open fires 
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Table S2: Single outcome models of fully adjustedA within school effects of exposures using the synthesis sampleB, stratified by country-level affluence. Mixed logistic 
regression models with random intercepts at the school, centre and country levels.  
Age Exposure 
Affluent Countries  (n = 41,831) Non-affluent Countries (n = 75,032)
Rhinoconjunctivitis 
OR (95% CI)
Asthma
OR (95% CI)
Eczema
OR (95% CI)
Rhinoconjunctivitis 
OR (95% CI)
Asthma
OR (95% CI)
Eczema
OR (95% CI)
6-7 years 
Low birthweight 1.02 (0.89, 1.16) 1.17 (1.03, 1.31) 0.93 (0.80, 1.07) 1.05 (0.95, 1.16) 1.14 (1.03, 1.26) 0.87 (0.77, 0.99) 
Breastfed ever 1.03 (0.96, 1.11) 1.02 (0.96, 1.10) 1.15 (1.06, 1.25) 0.96 (0.89, 1.04) 0.87 (0.81, 0.94) 1.05 (0.96, 1.15) 
Farm animals (prenatal) 1.16 (0.98, 1.38) 0.98 (0.83, 1.14) 1.00 (0.83, 1.21) 1.20 (1.07, 1.34) 1.32 (1.18, 1.49) 1.20 (1.06, 1.36) 
Farm animals (1st year) 0.88 (0.75, 1.03) 0.94 (0.81, 1.08) 0.95 (0.80, 1.13) 1.19 (1.07, 1.33) 1.02 (0.91, 1.13) 1.25 (1.11, 1.40) 
Cat (1st year) 1.05 (0.95, 1.16) 1.10 (1.01, 1.20) 0.99 (0.90, 1.09) 1.11 (1.01, 1.22) 1.36 (1.24, 1.49) 1.23 (1.11, 1.36) 
Dog (1st year) 1.05 (0.97, 1.14) 0.98 (0.91, 1.06) 0.98 (0.90, 1.07) 1.07 (1.00, 1.15) 1.06 (0.99, 1.14) 1.10 (1.02, 1.18) 
Paracetamol (1st year) 1.39 (1.27, 1.52) 1.41 (1.30, 1.53) 1.28 (1.17, 1.41) 1.40 (1.31, 1.50) 1.30 (1.21, 1.39) 1.31 (1.22, 1.41) 
Antibiotics (1st year) 1.60 (1.49, 1.72) 1.70 (1.59, 1.82) 1.43 (1.33, 1.54) 1.56 (1.46, 1.66) 1.62 (1.52, 1.73) 1.36 (1.27, 1.45) 
2 or more siblings 0.87 (0.81, 0.94) 0.91 (0.85, 0.98) 0.95 (0.88, 1.02) 1.06 (1.00, 1.13) 1.01 (0.95, 1.07) 0.93 (0.87, 1.00) 
Heavy truck traffic (current) 1.16 (1.08, 1.24) 1.16 (1.09, 1.24) 1.08 (1.01, 1.17) 1.17 (1.11, 1.24) 1.20 (1.14, 1.27) 1.14 (1.07, 1.21) 
Fast food (current) 0.99 (0.92, 1.06) 1.07 (1.00, 1.14) 1.05 (0.97, 1.13) 0.98 (0.92, 1.05) 1.09 (1.03, 1.16) 0.96 (0.89, 1.03) 
Television (current) 0.88 (0.81, 0.95) 1.05 (0.98, 1.14) 0.92 (0.85, 1.00) 1.00 (0.92, 1.08) 1.05 (0.97, 1.14) 1.01 (0.93, 1.11) 
Paternal tobacco (current) 1.04 (0.97, 1.11) 1.11 (1.03, 1.18) 1.06 (0.98, 1.14) 1.10 (1.03, 1.17) 1.10 (1.03, 1.17) 1.03 (0.96, 1.11) 
Maternal tobacco (current) 1.06 (0.98, 1.15) 1.20 (1.12, 1.29) 1.01 (0.92, 1.10) 1.03 (0.94, 1.13) 1.22 (1.11, 1.33) 1.12 (1.02, 1.24) 
Paracetamol (current) 2.19 (2.01, 2.40) 2.36 (2.19, 2.56) 1.65 (1.50, 1.81) 1.94 (1.82, 2.07) 1.90 (1.78, 2.02) 1.35 (1.25, 1.46) 
Open fire cooking (current) 1.52 (1.05, 2.21) 1.62 (1.17, 2.24) 1.09 (0.72, 1.65) 0.88 (0.71, 1.09) 1.10 (0.92, 1.32) 1.13 (0.94, 1.36) 
Age Exposure 
Affluent Countries (n = 46,932) Non-Affluent Countries (n = 177,504) 
Rhinoconjunctivitis 
OR (95% CI) 
Asthma
OR (95% CI) 
Eczema 
OR (95% CI) 
Rhinoconjunctivitis 
OR (95% CI) 
Asthma
OR (95% CI) 
Eczema 
OR (95% CI) 
13-14 years 
2 or more siblings 1.00 (0.94, 1.05) 1.01 (0.95, 1.07) 1.06 (0.97, 1.16) 1.05 (1.02, 1.09) 1.03 (0.99, 1.07) 1.08 (1.03, 1.14) 
Heavy truck traffic (current) 1.22 (1.15, 1.28) 1.15 (1.08, 1.22) 1.33 (1.22, 1.45) 1.23 (1.20, 1.27) 1.21 (1.17, 1.26) 1.31 (1.25, 1.36) 
Fast food (current) 1.06 (1.00, 1.11) 1.03 (0.97, 1.09) 1.06 (0.97, 1.16) 1.06 (1.02, 1.09) 1.08 (1.04, 1.12) 1.06 (1.02, 1.11) 
Television (current) 0.98 (0.90, 1.08) 1.05 (0.95, 1.16) 0.95 (0.83, 1.10) 1.01 (0.97, 1.06) 1.01 (0.95, 1.06) 1.10 (1.03, 1.18) 
Paternal tobacco (current) 1.02 (0.97, 1.08) 1.10 (1.03, 1.16) 1.04 (0.95, 1.14) 1.12 (1.09, 1.16) 1.11 (1.07, 1.16) 1.18 (1.13, 1.23) 
Maternal tobacco (current) 1.13 (1.06, 1.20) 1.27 (1.20, 1.36) 1.07 (0.97, 1.19) 1.14 (1.09, 1.19) 1.19 (1.14, 1.25) 1.12 (1.06, 1.19) 
Paracetamol (current) 1.96 (1.85, 2.08) 1.99 (1.87, 2.11) 1.76 (1.61, 1.93) 1.70 (1.65, 1.76) 1.75 (1.68, 1.81) 1.54 (1.48, 1.61) 
Open fire cooking (current) 0.82 (0.62, 1.07) 1.06 (0.82, 1.37) 1.63 (1.16, 2.29) 1.20 (1.11, 1.30) 1.21 (1.11, 1.33) 1.46 (1.32, 1.63) 
AAdjusted for sex, mother's level of education and all other variables in the table for that age group. 
BSynthesis sample contains individuals with data present for all 3 outcomes, sex, maternal education and all exposures of interest.  
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Table S3: Fully adjustedA unimorbid two-way models split by country affluence. Mixed logistic regression models with random intercepts at the school, centre and 
country levels.
Exposure of Interest Asthma v Eczema, fully adjusted modelsA
Rhinoconjunctivitis v Asthma, 
fully adjusted modelsA
Eczema v Rhinoconjunctivitis, 
fully adjusted modelsA
Age 6-7 years 
Affluent countries
n=5,172 
Non-affluent countries
n=6,647 
Affluent countries
n=5,189 
Non-affluent countries
n=7,039 
Affluent countries
n=4,347 
Non-affluent countries
n=6,260 
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Low birthweight 1.42 (1.10, 1.82) 1.40 (1.13, 1.72) 0.81 (0.63, 1.05) 0.90 (0.74, 1.09) 0.85 (0.63, 1.14) 0.93 (0.75, 1.15)
Breastfed ever 0.86 (0.75, 0.99) 0.84 (0.72, 0.99) 1.03 (0.89, 1.18) 1.09 (0.94, 1.27) 1.12 (0.96, 1.31) 1.10 (0.93, 1.29) 
Farm animals (prenatal) 0.85 (0.63, 1.16) 1.13 (0.90, 1.42) 1.23 (0.90, 1.68) 0.92 (0.74, 1.15) 0.85 (0.60, 1.20) 1.01 (0.80, 1.27)
Farm animals (1st year) 1.08 (0.82, 1.43) 0.82 (0.67, 1.02) 1.00 (0.76, 1.33) 1.21 (0.98, 1.48) 1.02 (0.75, 1.40) 0.99 (0.81, 1.23) 
Cat (1st year) 1.08 (0.92, 1.27) 1.17 (0.98, 1.39) 0.91 (0.75, 1.09) 0.69 (0.57, 0.82) 1.06 (0.87, 1.29) 1.35 (1.12, 1.63)
Dog (1st year) 1.02 (0.87, 1.18) 0.89 (0.78, 1.01) 1.09 (0.93, 1.29) 1.00 (0.88, 1.14) 0.93 (0.78, 1.11) 1.12 (0.98, 1.27) 
Paracetamol (1st year) 1.15 (0.99, 1.35) 0.98 (0.86, 1.11) 1.04 (0.88, 1.23) 1.05 (0.92, 1.20) 0.88 (0.73, 1.05) 0.97 (0.86, 1.11)
Antibiotics (1st year) 1.26 (1.11, 1.43) 1.27 (1.12, 1.43) 0.87 (0.76, 1.00) 0.90 (0.80, 1.02) 0.93 (0.81, 1.08) 0.84 (0.75, 0.95) 
2 or more siblings 0.98 (0.86, 1.12) 1.04 (0.93, 1.18) 0.89 (0.77, 1.03) 1.11 (0.99, 1.24) 1.11 (0.96, 1.30) 0.89 (0.79, 1.00)
Heavy truck traffic (current) 1.03 (0.91, 1.17) 1.11 (1.00, 1.24) 0.91 (0.80, 1.05) 0.98 (0.88, 1.09) 1.04 (0.90, 1.20) 0.89 (0.80, 1.00) 
Fast food (current) 0.99 (0.87, 1.13) 1.20 (1.07, 1.36) 0.93 (0.81, 1.07) 0.87 (0.77, 0.97) 1.07 (0.92, 1.25) 0.96 (0.85, 1.09)
Television (current) 1.19 (1.02, 1.38) 1.06 (0.90, 1.24) 0.83 (0.71, 0.97) 0.88 (0.76, 1.02) 1.09 (0.92, 1.28) 1.13 (0.96, 1.33) 
Paternal tobacco (current) 1.02 (0.89, 1.17) 1.01 (0.90, 1.15) 0.93 (0.81, 1.07) 1.00 (0.89, 1.13) 1.04 (0.89, 1.21) 0.96 (0.85, 1.09)
Maternal tobacco (current) 1.28 (1.11, 1.48) 1.00 (0.84, 1.19) 0.81 (0.70, 0.95) 0.84 (0.71, 1.00) 0.93 (0.78, 1.10) 1.22 (1.03, 1.45) 
Paracetamol (current) 1.58 (1.34, 1.87) 1.39 (1.22, 1.58) 0.94 (0.79, 1.12) 1.00 (0.89, 1.13) 0.67 (0.55, 0.82) 0.67 (0.59, 0.77)
Open fire cooking (current) 1.21 (0.62, 2.35) 1.00 (0.73, 1.38) 1.00 (0.50, 2.03) 0.72 (0.49, 1.04) 0.82 (0.37, 1.81) 1.54 (1.04, 2.26) 
Age 13-14 years 
Affluent countries
n=4,774 
Non-affluent countries
n=15,915 
Affluent countries
n=7,941 
Non-affluent countries
n=25,502 
Affluent countries
n=5,557 
Non-affluent countries
n=21,405 
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
2 or more siblings 0.93 (0.80, 1.07) 0.95 (0.87, 1.03) 0.98 (0.89, 1.09) 1.01 (0.95, 1.08) 1.07 (0.93, 1.23) 1.03 (0.95, 1.11) 
Heavy truck traffic (current) 0.90 (0.78, 1.04) 0.93 (0.87, 1.01) 1.08 (0.98, 1.19) 1.01 (0.96, 1.08) 1.07 (0.93, 1.23) 1.08 (1.01, 1.15)
Fast food (current) 0.92 (0.80, 1.06) 1.03 (0.95, 1.11) 1.01 (0.91, 1.11) 1.02 (0.96, 1.08) 1.07 (0.93, 1.23) 0.99 (0.92, 1.06) 
Television (current) 1.08 (0.85, 1.38) 0.96 (0.85, 1.08) 0.92 (0.77, 1.08) 0.95 (0.87, 1.04) 1.03 (0.81, 1.29) 1.05 (0.94, 1.17)
Paternal tobacco (current) 1.06 (0.92, 1.24) 0.93 (0.86, 1.01) 0.90 (0.81, 1.00) 1.03 (0.96, 1.09) 1.04 (0.90, 1.21) 1.04 (0.97, 1.12) 
Maternal tobacco (current) 1.30 (1.11, 1.53) 1.09 (0.98, 1.21) 0.83 (0.74, 0.93) 0.92 (0.85, 1.00) 0.92 (0.79, 1.09) 0.99 (0.90, 1.09)
Paracetamol (current) 1.29 (1.10, 1.51) 1.15 (1.06, 1.24) 0.97 (0.87, 1.08) 0.98 (0.92, 1.05) 0.79 (0.68, 0.92) 0.87 (0.81, 0.94) 
Open fire cooking (current) 0.77 (0.41, 1.45) 0.92 (0.76, 1.11) 0.73 (0.45, 1.19) 0.97 (0.84, 1.13) 1.87 (0.97, 3.59) 1.20 (1.01, 1.44)
AAdjusted for sex, mother's level of education and all other variables in the table for that age group. 
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Figure S1. Synthesis sample data flowchart, age 6-7 years 
Figure S1 shows the data flow through the exclusions to the final analysed sample for the 6-7 
year-old children. 
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Figure S2. Synthesis sample data flowchart, age 13-14 years 
Figure S2 shows the data flow through the exclusions to the final analysed sample for the 13-14 
year-old adolescents. 
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Figure S3. Triangular graphs showing unimorbid two-way comparisons of early life risk factor effects for 6-7-year-old children.
Figure S3: Each triangular plot shows the OR (labelled) and 95% confidence interval for two-way associations between the risk factor and two of the three diseases Asthma 
(A), Eczema (E) and Rhinoconjunctivitis (R) using a sample of unimorbid individuals. The odds ratio is always over 1 and relates to the increased chance of an individual with 
that risk factor as having one disease over the other. It indicates a relative strength of association (one disease compared to another) rather than an absolute strength of 
association (a disease compared to no disease). An equilateral central triangle denotes a risk factor that has a similar strength of effect on all three diseases. The further 
from equilateral the triangle is, the more that risk factor effect differs in strength between diseases. Early life risk factors in 6-7 year-old children includes factors from the 
first year of the child’s life (except prenatal farm animals which is mother’s contact with farm animals during pregnancy with the child). The possible range of OR graphed is 
from 1 in the centre to 2 at either extreme, on the log scale. 
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Figure S4. Triangular graphs showing unimorbid two-way comparisons of current risk factor effects for 6-7-year-old children. 
Figure S4: Each triangular plot shows the OR (labelled) and 95% confidence interval for two-way associations between the risk factor and two of the three diseases Asthma 
(A), Eczema (E) and Rhinoconjunctivitis (R) using a sample of unimorbid individuals. The odds ratio is always over 1 and relates to the increased chance of an individual with 
that risk factor as having one disease over the other. It indicates a relative strength of association (one disease compared to another) rather than an absolute strength of 
association (a disease compared to no disease). An equilateral central triangle denotes a risk factor that has a similar strength of effect on all three diseases. The further 
from equilateral the triangle is, the more that risk factor effect differs in strength between diseases. Current risk factors in 6-7 year-old children includes factors from the 
previous 12 months. The possible range of OR graphed is from 1 in the centre to 2 at either extreme, on the log scale. 
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Figure S5. Triangular graphs showing unimorbid two-way comparisons of current risk factor effects for 13-14-year-old adolescents. 
Figure S5: Each triangular plot shows the OR (labelled) and 95% confidence interval for two-way associations between the risk factor and two of the three diseases Asthma 
(A), Eczema (E) and Rhinoconjunctivitis (R) using a sample of unimorbid individuals. The odds ratio is always over 1 and relates to the increased chance of an individual with 
that risk factor as having one disease over the other. It indicates a relative strength of association (one disease compared to another) rather than an absolute strength of 
association (a disease compared to no disease). An equilateral central triangle denotes a risk factor that has a similar strength of effect on all three diseases. The further 
from equilateral the triangle is, the more that risk factor effect differs in strength between diseases. Current risk factors in 13-14 year-old adolescents includes factors from 
the previous 12 months. The possible range of OR graphed is from 1 in the centre to 2 at either extreme, on the log scale.  
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Figure S6. Triangular graphs showing unimorbid two-way comparisons of effects of early life risk factors for 6-7-year-old children in affluent and non-affluent countries. 
Figure S6: Each triangular plot shows the OR (labelled) and 95% confidence interval for two-way associations between the risk factor and two of the three diseases Asthma (A), Eczema (E) 
and Rhinoconjunctivitis (R) using a sample of unimorbid individuals, stratified by affluent countries (red) and non-affluent countries (blue). The odds ratio is always over 1 and relates to the 
increased chance of an individual with that risk factor as having one disease over the other. It indicates a relative strength of association (one disease compared to another) rather than an 
absolute strength of association (a disease compared to no disease). An equilateral central triangle denotes a risk factor that has a similar strength of effect on all three diseases. The further 
from equilateral the triangle is, the more that risk factor effect differs in strength between diseases. Early life risk factors in 6-7 year-old children includes factors from the first year of the 
child’s life (except prenatal farm animals which is mother’s contact with farm animals during pregnancy with the child). The possible range of OR graphed is from 1 in the centre to 2 
at either extreme, on the log scale.  
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Figure S7. Triangular graphs showing unimorbid two-way comparisons of effects of current risk factors for 6-7-year-old children in affluent and non-affluent countries. 
Figure S7: Each triangular plot shows the OR (labelled) and 95% confidence interval for two-way associations between the risk factor and two of the three diseases Asthma (A), Eczema (E) 
and Rhinoconjunctivitis (R) using a sample of unimorbid individuals, stratified by affluent countries (red) and non-affluent countries (blue). The odds ratio is always over 1 and relates to the 
increased chance of an individual with that risk factor as having one disease over the other. It indicates a relative strength of association (one disease compared to another) rather than an 
absolute strength of association (a disease compared to no disease). An equilateral central triangle denotes a risk factor that has a similar strength of effect on all three diseases. The further 
from equilateral the triangle is, the more that risk factor effect differs in strength between diseases. Current risk factors in 6-7 year-old children includes factors from the previous 12 months. 
The possible range of OR graphed is from 1 in the centre to 2 at either extreme, on the log scale. 
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Figure S8. Triangular graphs showing unimorbid two-way comparisons of effects of current risk factors for 13-14-year-old adolescents in affluent and non-affluent 
countries. 
Figure S8: Each triangular plot shows the OR (labelled) and 95% confidence interval for two-way associations between the risk factor and two of the three diseases Asthma (A), Eczema (E) 
and Rhinoconjunctivitis (R) using a sample of unimorbid individuals, stratified by affluent countries (red) and non-affluent countries (blue). The odds ratio is always over 1 and relates to the 
increased chance of an individual with that risk factor as having one disease over the other. It indicates a relative strength of association (one disease compared to another) rather than an 
absolute strength of association (a disease compared to no disease). An equilateral central triangle denotes a risk factor that has a similar strength of effect on all three diseases. The further 
from equilateral the triangle is, the more that risk factor effect differs in strength between diseases. Current risk factors in 13-14 year-old adolescents includes factors from the previous 12 
months. The possible range of OR graphed is from 1 in the centre to 2 at either extreme, on the log scale.
